Comparative Pharmacology
Head-to-head clinical analysis: OPVEE versus REVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPVEE versus REVEX.
OPVEE vs REVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opvee is a naloxone-containing nasal spray. Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and sedation.
Nalmefene is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, reversing or preventing opioid effects.
2 mg intranasally as a single dose; may repeat every 2-3 minutes if response is inadequate; maximum total dose of 4 mg.
0.5 mg to 1 mg intravenous, intramuscular, or subcutaneous, repeated every 2 to 5 minutes as needed, up to a maximum of 2 mg total dose per episode.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours (mean 2.8 hours) in healthy adults. Context: Despite short half-life, clinical antagonism of opioids can persist for 1-2 hours, potentially shorter than the opioid; repeat dosing may be needed.
Terminal elimination half-life: 2.4-4.2 hours in adults; prolonged in renal impairment (up to 50 hours).
Primarily renal excretion of unchanged drug (approximately 50-70%) and conjugated metabolites (glucuronide); the remainder is eliminated via biliary/fecal routes. Total renal clearance accounts for ~60% of systemic clearance.
Renal: 60% as unchanged drug and metabolites; fecal: 40% via biliary elimination.
Category C
Category C
Opioid Antagonist
Opioid Antagonist